INDGN2024-10-012024-12-31 INDGN2024-10-012024-12-31 INDGN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member INDGN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member INDGN2024-12-31 INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue03Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue04Member INDGN2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member INDGN2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member INDGN2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue03Member INDGN2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue04Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults03Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults04Member INDGN2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member INDGN2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member INDGN2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults03Member INDGN2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults04Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets03Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets04Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member INDGN2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member INDGN2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member INDGN2024-12-31in-bse-fin:OneReportableSegmentLiabilities03Member INDGN2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities04Member INDGN2024-12-31in-bse-fin:OneReportableSegmentLiabilities04Member INDGN2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDGN2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDGN2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member INDGN2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544172 INDGN NOTLISTED Indegene Limited Equity 2024-04-01 2025-03-31 2025-01-30 2025-01-24 INR Millions Third quarter 15:46:00 17:00:00 2025-01-30 2025-01-30 Not applicable Multi segment 2024-10-01 2024-12-31 Unaudited Consolidated 7204000000.00 377000000.00 7581000000.00 0.00 0.00 0.00 4438000000.00 32000000.00 200000000.00 1448000000.00 6118000000.00 1463000000.00 0.00 1463000000.00 338000000.00 28000000.00 366000000.00 0.00 1097000000.00 0.00 0.00 0.00 0.00 1097000000.00 132000000.00 1229000000.00 1097000000.00 0.00 1229000000.00 0.00 478000000.00 2 4.59 4.55 0.00 0.00 4.59 4.55 EPS is not annualized for the quarter and nine months period ended. Notes to the Statement of Consolidated Financial Results for the quarter and nine months ended 31 December 2024 (All amounts in INR millions, except share data and where otherwise stated) 1. The above Consolidated Financial Results of the Group have been prepared in accordance with Indian Accounting Standards ( Ind AS ) 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ( Ind AS ) prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( the regulations ). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. ^ in the financial information denote amounts less than INR 0.50 million. 2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30 January 2025. The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter and nine months ended 31 December 2024 and have issued an unmodified review report on the same. 3. The Consolidated Financial Results for the quarter and nine months ended 31 December 2024, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations). 4. During the nine months ended 31 December 2024, the Company has completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of INR 2 each at an issue price of INR 452 per share, comprising fresh issue of 16,833,818 shares aggregating to INR 7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to INR 10,818. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company was not mandatorily required to prepare and publish results for the quarter and nine months ended 31 December 2023 in accordance with the regulations. 5. Exceptional items - On 12 October 2022, the Group had obtained control of Cult Health LLC by acquiring 100% interest to enhance the Group's commercialization portfolio adding market development and brand strategy competencies along with patient engagement platforms. The acquisition was consummated for a consideration of INR 5,347. The contingent consideration is based on the performance of Cult during the fiscal year beginning 01 April 2023 and ending 31 March 2026 and range of contingent consideration payable is between INR Nil to INR 3,040. Cult Health LLC is part of Omnichannel Activation segment. Note 5 is continued in Segment tab Multi segment 2024-04-01 2024-12-31 Unaudited Consolidated 20837000000.00 816000000.00 21653000000.00 0.00 0.00 0.00 13301000000.00 189000000.00 595000000.00 3668000000.00 17753000000.00 3900000000.00 0.00 3900000000.00 1053000000.00 -44000000.00 1009000000.00 0.00 2891000000.00 0.00 0.00 0.00 0.00 2891000000.00 230000000.00 3121000000.00 2891000000.00 0.00 3121000000.00 0.00 478000000.00 2 12.23 12.12 0.00 0.00 12.23 12.12 Other Expenses 1448000000.00 Other Expenses 3668000000.00 Enterprise Commercial Solutions 4003000000.00 Enterprise Medical Solutions 2052000000.00 Omnichannel Activation 889000000.00 Others* 260000000.00 Enterprise Commercial Solutions 11615000000.00 Enterprise Medical Solutions 5918000000.00 Omnichannel Activation 2510000000.00 Others* 794000000.00 7204000000.00 20837000000.00 0.00 0.00 7204000000.00 20837000000.00 Enterprise Commercial Solutions 903000000.00 Enterprise Medical Solutions 534000000.00 Omnichannel Activation 132000000.00 Others* -62000000.00 Enterprise Commercial Solutions 2569000000.00 Enterprise Medical Solutions 1496000000.00 Omnichannel Activation 311000000.00 Others* -229000000.00 1507000000.00 4147000000.00 32000000.00 189000000.00 12000000.00 Notes to the Statement of Consolidated Financial Results for the quarter and nine months ended 31 December 2024 (Contd.) 5. Exceptional items (Contd.)- The Group carried out remeasurement of the change in fair value of contingent consideration towards earnout payout, which was measured at its fair value on acquisition and recognised a resultant gain of INR 935. Change in fair value movement of contingent consideration has been recognized as an exceptional item during the year ended 31 March 2024. Further, the Group also carried out the assessment of recoverable value of the investments made in Cult Health LLC owing to reduction in revenues from certain customers and its impact on the future cash flows. The recoverable amount of this CGU estimated to be lower than carrying value, resulting into an impairment charge of INR 911. The impairment charge had been recognized as an exceptional item during the year ended 31 March 2024. 6. Basis the Management’s assessment/ remeasurement of the fair value of the contingent consideration payable, the Group has reversed contingent consideration pertaining to acquisition of Cult Health LLC and Trilogy Writing & Consulting GmbH amounting to INR 103 and INR 55, respectively and has been accounted for the same as other income during the quarter and nine months ended 31 December 2024. Further, the Group had invested in TriloDocs at the time of acquisition of Trilogy via convertible loan of EUR 1.5 Mn. Based on assessment of recoverability of the loan given to TriloDocs GmbH aggregating to INR 136, the Group has fully provided for the same during the quarter and nine months ended 31 December 2024 and accounted it as other expenses. 7. Operating Segment: The Segment results of the Group has been prepared in accordance with Ind-AS 108 on Operating Segments . The Group has identified business segments (industry practice) as reportable segments. The business segments comprise: 1) Enterprise Medical Solutions, 2) Enterprise Commercial Solutions, 3) Omnichannel Activation. *Others mainly comprises of consultancy and clinical business. Operating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker. In deciding how to allocate resources and assessing performance, the Group's chief operating decision maker is the Chief Executive Officer and Executive Director. Assets and liabilities used in the Group’s business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous. Other unallocable expenditure net of unallocable income for the quarter ended 31 December 2024 includes depreciation and amortisation expense (INR 200) and unallocable expenses (INR 189) net of other income (INR 377). Other unallocable expenditure net of unallocable income for the nine months ended 31 December 2024 includes depreciation and amortisation expense (INR 595) and unallocable expenses (INR 279) net of other income (INR 816). 58000000.00 1463000000.00 3900000000.00 Enterprise Commercial Solutions 0.00 Enterprise Medical Solutions 0.00 Omnichannel Activation 0.00 Others* 0.00 0.00 Enterprise Commercial Solutions 0.00 Enterprise Medical Solutions 0.00 Omnichannel Activation 0.00 Others* 0.00 0.00 Remeasurement of defined benefit obligation 11000000.00 Remeasurement of defined benefit obligation 18000000.00 11000000.00 18000000.00 3000000.00 5000000.00 Exchange differences on translating the financial statements of foreign operations 124000000.00 Exchange differences on translating the financial statements of foreign operations 217000000.00 124000000.00 217000000.00 0.00 0.00